FARALLON CAPITAL MANAGEMENT LLC

Add to watchlist

$902 Million is the total value of FARALLON CAPITAL MANAGEMENT LLC's 314 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 46.4% .

All

			Value		Shares		↓ Weighting
SPY	Sell	SPDR S&P 500 ETF TRput	$1,395,825,000	-45.9%	3,700,000	-35.2%	7.62%	-38.8%
BSX	Sell	BOSTON SCIENTIFIC CORP	$560,811,000	-19.6%	15,047,257	-4.4%	3.06%	-9.1%
ARMK	Sell	ARAMARK	$490,326,000	-20.9%	16,008,017	-2.9%	2.68%	-10.6%
WAB	Sell	WABTEC	$327,494,000	-30.6%	3,989,933	-18.7%	1.79%	-21.6%
MSFT	Sell	MICROSOFT CORP	$326,913,000	-17.6%	1,272,878	-1.0%	1.78%	-6.8%
GOOG	Sell	ALPHABET INCcap stk cl c	$313,696,000	-33.1%	143,407	-14.5%	1.71%	-24.3%
SJR	Sell	SHAW COMMUNICATIONS INCcl b conv	$292,213,000	-7.0%	9,917,000	-2.1%	1.59%	+5.1%
FB	Sell	META PLATFORMS INCcl a	$287,193,000	-37.4%	1,781,040	-13.7%	1.57%	-29.3%
BX	Sell	BLACKSTONE INC	$257,401,000	-30.6%	2,821,451	-3.5%	1.40%	-21.6%
AON	Sell	AON PLC	$250,394,000	-24.2%	928,486	-8.4%	1.37%	-14.3%
SHW	Sell	SHERWIN WILLIAMS CO	$237,925,000	-22.2%	1,062,592	-13.3%	1.30%	-12.1%
NOW	Sell	SERVICENOW INC	$233,076,000	-15.0%	490,150	-0.4%	1.27%	-3.9%
EXEL	Sell	EXELIXIS INC	$211,828,000	-11.2%	10,174,273	-3.3%	1.16%	+0.4%
NYT	Sell	NEW YORK TIMES COcl a	$191,974,000	-42.9%	6,880,804	-6.2%	1.05%	-35.5%
ALNY	Sell	ALNYLAM PHARMACEUTICALS INC	$114,917,000	-31.3%	787,910	-23.0%	0.63%	-22.3%
ABBV	Sell	ABBVIE INC	$77,425,000	-58.3%	505,515	-55.8%	0.42%	-52.9%
BPMC	Sell	BLUEPRINT MEDICINES CORP	$61,217,000	-29.4%	1,211,987	-10.7%	0.33%	-20.1%
CTLT	Sell	CATALENT INC	$45,036,000	-43.3%	419,755	-41.4%	0.25%	-35.9%
IOVA	Sell	IOVANCE BIOTHERAPEUTICS INC	$35,072,000	-65.9%	3,176,773	-48.6%	0.19%	-61.5%
ZEN	Sell	ZENDESK INC	$32,591,000	-57.0%	440,000	-30.2%	0.18%	-51.4%
GBIO	Sell	GENERATION BIO CO	$19,006,000	-26.0%	2,897,300	-17.2%	0.10%	-16.1%
HTA	Sell	HEALTHCARE TR AMER INCcl a new	$13,955,000	-78.2%	500,000	-75.5%	0.08%	-75.4%
KRTX	Sell	KARUNA THERAPEUTICS INC	$12,651,000	-71.5%	100,000	-71.4%	0.07%	-67.8%
	Sell	CARIBOU BIOSCIENCES INC	$11,967,000	-50.9%	2,203,895	-17.1%	0.06%	-44.9%
GPOR	Sell	GULFPORT ENERGY CORP	$11,952,000	-57.3%	150,326	-51.8%	0.06%	-51.9%
	Sell	VENTYX BIOSCIENCES INC	$11,382,000	-24.7%	930,648	-16.5%	0.06%	-15.1%
NTRA	Sell	NATERA INC	$8,171,000	-81.8%	230,552	-79.1%	0.04%	-79.2%
CDK	Sell	CDK GLOBAL INC	$5,834,000	-67.6%	106,514	-71.2%	0.03%	-63.2%
RC	Sell	READY CAPITAL CORP	$5,633,000	-30.1%	472,537	-11.7%	0.03%	-20.5%
QTRX	Sell	QUANTERIX CORP	$4,209,000	-73.5%	260,000	-52.3%	0.02%	-70.1%
	Sell	UTA ACQUISITION CORPORATION	$3,412,000	-1.0%	344,100	-1.7%	0.02%	+11.8%
RCEL	Sell	AVITA MEDICAL INC	$2,755,000	-59.4%	580,000	-27.5%	0.02%	-54.5%
	Sell	THESEUS PHARMACEUTICALS INC	$2,266,000	-62.5%	409,717	-21.8%	0.01%	-58.6%
	Sell	BETTER THERAPEUTICS INC	$1,560,000	-31.3%	1,000,000	-12.8%	0.01%	-18.2%
IKNA	Sell	IKENA ONCOLOGY INC	$1,285,000	-73.4%	290,000	-63.4%	0.01%	-69.6%
ANNX	Sell	ANNEXON INC	$490,000	-29.8%	130,000	-49.2%	0.00%	0.0%
	Sell	TERRAN ORBITAL CORPORATION*w exp 03/25/202	$117,000	-29.1%	239,233	-28.2%	0.00%	0.0%
VGIIWS	Exit	VIRGIN GROUP ACQUISIT CORP II*w exp 03/13/202	$0	–	-200,000	-100.0%	0.00%	–
CASWS	Exit	CASCADE ACQUISITION CORP*w exp 11/30/202	$0	–	-495,000	-100.0%	0.00%	–
EDU	Exit	NEW ORIENTAL ED & TECHNOLOGYspon adr	$0	–	-130,000	-100.0%	-0.00%	–
CMPX	Exit	COMPASS THERAPEUTICS INC	$0	–	-582,750	-100.0%	-0.00%	–
	Exit	DARIOHEALTH CORP	$0	–	-133,083	-100.0%	-0.00%	–
VCYT	Exit	VERACYTE INC	$0	–	-32,500	-100.0%	-0.00%	–
	Exit	PATRIA LATIN AMRCN OPPRNTY Aunit 04/22/2026	$0	–	-100,000	-100.0%	-0.01%	–
FATE	Exit	FATE THERAPEUTICS INC	$0	–	-31,900	-100.0%	-0.01%	–
FOE	Exit	FERRO CORP	$0	–	-114,963	-100.0%	-0.01%	–
	Exit	SOUND POINT ACQUISITION CORPunit 02/25/2027	$0	–	-300,000	-100.0%	-0.02%	–
FGEN	Exit	FIBROGEN INC	$0	–	-364,764	-100.0%	-0.02%	–
PNT	Exit	POINT BIOPHARMA GLOBAL INC	$0	–	-626,322	-100.0%	-0.02%	–
GBT	Exit	GLOBAL BLOOD THERAPEUTICS IN	$0	–	-169,458	-100.0%	-0.03%	–
ARWR	Exit	ARROWHEAD PHARMACEUTICALS IN	$0	–	-142,700	-100.0%	-0.03%	–
ZEAL	Exit	ZEALAND PHARMA A/Ssponsored adr	$0	–	-496,890	-100.0%	-0.04%	–
PBCT	Exit	PEOPLES UNITED FINANCIAL INC	$0	–	-485,000	-100.0%	-0.05%	–
VGII	Exit	VIRGIN GROUP ACQUISIT CORP II	$0	–	-1,000,000	-100.0%	-0.05%	–
CAS	Exit	CASCADE ACQUISITION CORP	$0	–	-990,000	-100.0%	-0.05%	–
ZNGA	Exit	ZYNGA INCput	$0	–	-1,500,000	-100.0%	-0.07%	–
PACB	Exit	PACIFIC BIOSCIENCES CALIF IN	$0	–	-1,631,800	-100.0%	-0.07%	–
VNE	Exit	VEONEER INC	$0	–	-427,500	-100.0%	-0.08%	–
RGEN	Exit	REPLIGEN CORP	$0	–	-222,979	-100.0%	-0.20%	–
DIDI	Exit	DIDI GLOBAL INCsponsored ads	$0	–	-16,868,328	-100.0%	-0.20%	–
OCDX	Exit	ORTHO CLINICAL DIAGNOSTICS H	$0	–	-2,426,913	-100.0%	-0.22%	–
EXAS	Exit	EXACT SCIENCES CORP	$0	–	-802,898	-100.0%	-0.27%	–
NLSN	Exit	NIELSEN HLDGS PLC	$0	–	-3,720,000	-100.0%	-0.49%	–
PLAN	Exit	ANAPLAN INC	$0	–	-1,570,000	-100.0%	-0.49%	–
HZNP	Exit	HORIZON THERAPEUTICS PUB L	$0	–	-1,480,377	-100.0%	-0.75%	–
AVGO	Exit	BROADCOM INC	$0	–	-408,850	-100.0%	-1.24%	–
CERN	Exit	CERNER CORP	$0	–	-3,339,955	-100.0%	-1.51%	–
RTX	Exit	RAYTHEON TECHNOLOGIES CORP	$0	–	-3,385,484	-100.0%	-1.62%	–
ZNGA	Exit	ZYNGA INCcl a	$0	–	-44,475,000	-100.0%	-1.98%	–

Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Farallon Capital Europe LLP #1

Original filings

The following EDGAR filing(s) were analyzed to create this report:

View 13F-HR/A filed 2023-11-14
View 13F-HR/A filed 2023-02-14
View 13F-HR/A filed 2023-05-15
View 13F-HR filed 2022-08-15
View 13F-HR/A filed 2022-11-14

Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings

Name	Quarters owned	Latest quarter owned	Max weighting
MICROSOFT CORP	41	Q3 2023	3.7%
RADIUS HEALTH INC	33	Q2 2022	1.7%
GRIFOLS S A	33	Q4 2021	0.9%
ALPHABET INC	32	Q3 2023	4.2%
SPDR S&P 500 ETF TR	31	Q3 2023	25.3%
VISA INC	30	Q3 2023	2.9%
WABTEC CORP	27	Q3 2023	3.6%
EXELIXIS INC	27	Q3 2023	2.8%
ELEVANCE HEALTH INC	26	Q3 2023	2.6%
SAVARA INC	26	Q3 2023	0.3%

View FARALLON CAPITAL MANAGEMENT LLC's complete holdings history.

Latest significant ownerships (13-D/G)

FARALLON CAPITAL MANAGEMENT LLC Q2 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
	Filed	Shares	Percentage
Atento S.A.	March 15, 2023	2,230,357	15.4%
Metals Acquisition Corp	February 07, 2023	2,489,700	9.4%
Inflection Point Acquisition Corp.	February 06, 2023	1,900,000	5.8%
AMYRIS, INC.	February 24, 2022	1,068,904	0.3%
Swiftmerge Acquisition Corp.	February 14, 2022	291,060	1.3%
Caribou Biosciences, Inc.	February 11, 2022	2,428,150	4.0%
ENANTA PHARMACEUTICALS INC	February 11, 2022	287,000	1.4%
Protagonist Therapeutics, Inc	February 11, 2022	387,051	0.8%
Solid Power, Inc.	February 11, 2022	?	?
Better Therapeutics, Inc.	February 09, 2022	124,065	0.5%

View FARALLON CAPITAL MANAGEMENT LLC's complete significant-ownership history.

Latest filings

Type	Filed
13F-HR/A	2024-02-14
13F-HR/A	2024-02-14
13F-HR/A	2024-02-14
13F-HR/A	2024-02-14
13F-HR/A	2024-02-14
13F-HR/A	2024-02-14
13F-HR	2024-02-14
13F-HR/A	2024-02-12
SC 13G/A	2024-02-01
SC 13G/A	2024-01-23

View FARALLON CAPITAL MANAGEMENT LLC's complete filings history.

All filings

View complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

The reported total value is incorrect (901592876.0 != 18327026000.0)
The reported has been amended

Export FARALLON CAPITAL MANAGEMENT LLC's holdings

FARALLON CAPITAL MANAGEMENT LLC - Q2 2022 holdings